Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 9/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.43 |
| ▸ | SLC9A3 | P48764 | 1/20 | 0.43 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871097 | 1.00 | AKR1C3 (0.58) | AKR1C3AKR1C2PTGS2AKR1C1TBXAS1 | |
| SCHEMBL397247 | 0.86 | AKR1C3 (0.56) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL397248 | 0.86 | AKR1C3 (0.56) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL396069 | 0.83 | AKR1C3 (0.53) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL398495 | 0.83 | AKR1C3 (0.53) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL396068 | 0.83 | AKR1C3 (0.53) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL398494 | 0.83 | AKR1C3 (0.53) | AKR1C3AKR1C2TBXAS1SLC9A1SLC9A3 | |
| SCHEMBL8746676 | 0.82 | AKR1C3 (0.76) | AKR1C3TBXAS1SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL8746678 | 0.82 | AKR1C3 (0.76) | AKR1C3TBXAS1SLC9A1SLC9A3SLC9A2 | |
| SCHEMBL394850 | 0.80 | ALDH1A1 (0.54) | AKR1C3TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AKR1C3 2388/4885AKR1C2 3128/4885PTGS2 3826/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AKR1C3 1559/4885AKR1C2 1362/4885PTGS2 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.